Kurosaka, S., Satoh, T., Chow, E., Asano, Y., Tabata, K., Kimura, M., . . . Baba, S. (2012). EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy. Annals of Nuclear Medicine, 26, 485–491.
To evaluate the effect of Sr-89 radionuclide therapy on the quality of life of patients with prostate cancer with painful bone metastases
Sr-89 radionuclide therapy is an established alternative for the palliation of bone pain in prostate cancer. This study is to assess the Sr-89 radionuclide therapy on quality of life (QOL) in patients with prostate cancer and painful bone metastasis.
12-week, prospective, single-arm, open-label study
Three patients reduced their analgesic dosages within three months after Sr-89 treatment. No patients increased their analgesics dosages during the study period. According to the ECOG scale, performance status prior to the Sr-89 treatment was reported by the physician to be 0 or 1 in three patients (23.1%) and 2 or greater in the remaining 10 patients (76.9%). In the QLQ-C30, the mean score for global QOL was 29.9. Overall, there were no significant changes in patients' serum PSA and ALP after Se-89 therapy.
Using the EORTC QLQ-BM22 module, this study showed that Sr-89 therapy improves the comprehensive quality of life of patients with prostate cancer with bone metastases pain. This radionuclide therapy can provide not only reduced pain but also better psychosocial aspects and functional interference in this patient population.
Treatment with Sr-89 for prostate cancer with painful bone metastases could assist in pain management for this group of patients.